Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer

详细信息    查看全文

• 作者：Bonny Parkinson ; Rosalie Viney ; Marion Haas ; Stephen Goodall…
• 刊名：PharmacoEconomics
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：34
• 期：10
• 页码：1039-1050
• 全文大小：622 KB
• 刊物主题：Pharmacoeconomics and Health Outcomes; Quality of Life Research; Health Economics; Health Administration;
• 出版者：Springer International Publishing
• ISSN：1179-2027
• 卷排序：34

文摘

IntroductionEstimating the real-world cost-effectiveness of a new drug relies on understanding the differences between clinical trial data (pre-reimbursement) and clinical practice (post-reimbursement). This is important for decision makers when reviewing reimbursement decisions, prices, and considering other drugs for the same condition. Differences can arise from differences in patient characteristics, but also from the availability of new evidence and evolving treatment practices. This paper examines these issues using a case study.